Bank of America Securities: AKESO (09926) recorded a sequential increase in non-seasonally adjustedgrowth for the quarter.
Maintain a "buy" rating on Kangmei Pharmaceutical with a target price of HKD 162.8.
Bank of America Securities released a research report stating that AKESO (09926) cadonilimab, a monoclonal antibody, recorded a month-on-month increase despite the off-season. In February, AKESO's drug sales reached 71.3 million yuan, an increase of 319.6% year-on-year. Among them, cadonilimab sales were 44.3 million yuan, an increase of 249.5% year-on-year and 9.6% month-on-month, achieving positive month-on-month growth during the Lunar New Year holiday. Ivonescimab monthly sales reached 26.6 million yuan, showing continuous growth, with a year-on-year increase of 517.4%. The "Buy" rating for AKESO is maintained, with a target price of HK $162.8.
Related Articles
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
